Aviceda Therapeutics Announces Strategic Partnership with Queen's University Belfast (QUB)

Aviceda Therapeutics, a clinical-stage biotech company focused on developing next-generation immuno-modulators to treat diseases such as cancer, today announced a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (Queen’s). Aviceda’s HALOS™ (High-Affinity ...

Related Keywords

United States ,Massachusetts ,Cambridge ,Cambridgeshire ,United Kingdom ,Northern Ireland ,Craigavon ,Ireland ,Belfast ,Chris Scott ,Christopher Scott ,Mark Lawler ,Mohamed Genead ,Aviceda Glycotech ,Aviceda Glycotech Ltd ,Life Sciences ,Scientific Co ,Aviceda Interim Dean Of Research ,Island Cancer Research Institute ,Professor Of Digital Health ,Patrickg Johnston Centre For Cancer Research ,Professor Christopher Scott ,Cancer Research ,University Belfast ,Cancer Showcase Event ,Good Friday Agreement Conference ,Aviceda Therapeutics ,Patrickg Johnston Centre ,Professor Chris Scott ,Scientific Co Founder ,Chief Scientific Officer ,Interim Dean ,Good Friday ,Doctor Mohamed Genead ,Chief Executive ,Belfast Good Friday Agreement ,Professor Scott ,Cancer Knows No Borders ,Good Friday Agreement ,Digital Health ,Translational Cancer Genomics ,All Island Cancer Research Institute ,Cancer Showcase ,Showcase Event ,Michael Tolentino ,Chief Technology Officer ,Belfast Region City Deal ,All Island Cancer Research ,